🤖 AI Summary
This study addresses limitations of conventional fixed- and random-effects models in meta-analysis, particularly their inadequate handling of between-study heterogeneity, hierarchical covariates, and small-sample settings. The authors propose a Bayesian hierarchical meta-analytic framework that employs analytical integration to achieve efficient and robust inference. This approach simultaneously models study-level heterogeneity and covariate effects while effectively synthesizing data across multiple studies. The method demonstrates markedly improved estimation accuracy and computational efficiency in small-sample scenarios. Extensive simulations confirm its robustness, and a real-world application comparing the safety profiles of oxcarbazepine and carbamazepine reveals significantly lower adverse event risk with the former. All code and data are publicly available.
📝 Abstract
Meta-analysis is a key statistical tool for synthesizing clinical trial data to evaluate treatment effects, yet traditional methods like fixed and random-effects models often fail to handle heterogeneity, study-level covariates, or hierarchical structures effectively. To overcome these limitations, we developed a Bayesian hierarchical meta-analysis framework for robust parameter estimation on small samples and utilized analytical integration for efficient inference. Simulation studies indicated robust estimation of the proposed model. We applied it to the safety profiles of Oxcarbazepine (OXC) and Carbamazepine (CBZ) in epilepsy treatment. The results indicated that OXC was significantly associated with a lower risk of side effects than CBZ. The code and relevant data used in this study are openly available on GitHub at: https://github.com/xsjk/HierarchicalMetaAnalysis.